Trials / Completed
CompletedNCT00733005
Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05528)(COMPLETED)
Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg QD in the Relief of Nasal Congestion Associated With Seasonal Allergic Rhinitis (SAR)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 324 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This study seeks to prospectively demonstrate that Nasonex is better than placebo in relieving nasal congestion in patients with seasonal allergic rhinitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mometasone furoate nasal spray (MFNS) | MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days |
| DRUG | Matching placebo nasal spray | Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days |
Timeline
- Start date
- 2008-07-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2008-08-12
- Last updated
- 2024-05-21
- Results posted
- 2009-11-19
Source: ClinicalTrials.gov record NCT00733005. Inclusion in this directory is not an endorsement.